<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95363</article-id><article-id pub-id-type="doi">10.26442/20751753.2020.12.200309</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Proand synbiotics in the treatment of intestinal diseases: what effects can we expect?</article-title><trans-title-group xml:lang="ru"><trans-title>Про- и синбиотики в лечении заболеваний кишечника: на какие эффекты мы можем рассчитывать?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gaus</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Гаус</surname><given-names>Ольга Владимировна</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, ассистент каф. факультетской терапии</p></bio><email>gaus_olga@bk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Livzan</surname><given-names>Maria A.</given-names></name><name xml:lang="ru"><surname>Ливзан</surname><given-names>Мария Анатольевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. каф. факультетской терапии</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Omsk State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2020</year></pub-date><volume>22</volume><issue>12</issue><issue-title xml:lang="en">VOL 22, NO12 (2020)</issue-title><issue-title xml:lang="ru">ТОМ 22, №12 (2020)</issue-title><fpage>37</fpage><lpage>43</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/95363">https://consilium.orscience.ru/2075-1753/article/view/95363</self-uri><abstract xml:lang="en"><p>The relationship between intestinal microbiota and human health is widely recognized. The advent of molecular and genetic diagnostic methods has made it possible to make truly revolutionary discoveries in the field of understanding the role of the digestive tract microbiome. Many studies have proved the association of the composition of microbiota with the development of a number of diseases of the digestive tract, such as inflammatory bowel diseases, functional gastrointestinal disorders and some types of cancer. The food and pharmaceutical industry has presented a huge selection of food products, dietary supplements and medicines containing prebiotic and probiotic components. The use of agents that affect microbiota in the treatment of intestinal diseases in real clinical practice should be carried out strictly in accordance with the indications, in recommended doses.</p></abstract><trans-abstract xml:lang="ru"><p>Связь между кишечной микробиотой и состоянием здоровья человека является общепризнанной. Появление молекулярных и генетических методов диагностики позволило сделать поистине революционные открытия в области понимания роли микробиома пищеварительного тракта. Во многих исследованиях доказана ассоциация измененного под воздействием факторов окружающей среды состава микробиоты с развитием целого ряда заболеваний пищеварительного тракта, таких как воспалительные заболевания кишечника, функциональные гастроинтестинальные расстройства, некоторые виды рака. Одновременно с этим пищевая и фармацевтическая промышленность представила огромный выбор продуктов питания, биологически активных добавок и лекарственных средств, содержащих пребиотические и пробиотические компоненты. Несмотря на растущее число исследований по эффективности средств, влияющих на микробиоту, их применение в реальной клинической практике должно осуществляться строго в соответствии с показаниями, в рекомендованных дозах.</p></trans-abstract><kwd-group xml:lang="en"><kwd>microbiota</kwd><kwd>probiotics</kwd><kwd>prebiotics</kwd><kwd>synbiotics</kwd><kwd>metabiotics</kwd><kwd>functional gastrointestinal disorders</kwd><kwd>inflammatory bowel diseases</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>микробиота</kwd><kwd>пробиотики</kwd><kwd>пребиотики</kwd><kwd>синбиотики</kwd><kwd>метабиотики</kwd><kwd>функциональные гастроинтестинальные расстройства</kwd><kwd>воспалительные заболевания кишечника</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Jandhyala SM, Talukdar R, Subramanyam C et al. Role of the normal gut microbiota. World J Gastroenterol 2015; 21 (29): 8787-803.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Cresci GA. The gut microbiome: what we do and don't know. Nutr Clin Pract 2015; 30 (6): 734-6.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12 (5): 319-30.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140 (6): 805-20.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>He B, Xu W, Santini PA et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007; 26 (6): 812-26.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Alakomi HL, Skytta E, Saarela M et al. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000; 66 (5): 2001-5.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Velagapudi VR, Hezaveh R, Reigstad CS et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010; 51 (5): 1101-12.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Azad MAK, Sarker M, Wan D. Immunomodulatory effects of probiotics on cytokine profiles. Biomed Res Int 2018; 8063647: 2018.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Defois C, Ratel J, Garrait G et al. Food chemicals disrupt human gut microbiota activity and impact intestinal homeostasis as revealed by in vitro systems. Sci Rep 2018; 8 (1): 11006.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Clayton TA, Baker D, Lindon JC et al. Pharmacometabonomic identification of a significant hostmicrobiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009; 106 (34): 14728-33.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983; 220 (4594): 325-7.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Wallace BD, Wang H, Lane KT et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330 (6005): 831-5.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Dominguez-Bello MG, Costello EK, Contreras M et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 2010; 107 (26): 11971-5.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Sherman MP, Zaghouani H, Niklas V. Gut microbiota, the immune system, and diet influence the neonatal gut-brain axis. Pediatr Res 2015; 77 (1-2): 127-35.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Zimmer J, Lange B, Frick JS et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 2012; 66: 53-60.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505 (7484): 559-63.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>McDonald D, Hyde E, Debelius JW et al. American gut: an open platform for citizen science microbiome research. mSystems 2018; 3 (3): e00031-18.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Prideaux L, Kang S, Wagner J et al. Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2906-18.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Jernberg C, Ldfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1 (1): 56-66.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Ng KM, Ferreyra JA, Higginbottom SK et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013; 502 (7469): 96-9.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Chong PP, Chin VK, Looi CY et al. The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol 2019; 10: 1136.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Гаус О.В., Ливзан М.А. Синдром раздраженного кишечника: что мы знаем о симптомах сегодня? Consilium Medicum. 2019; 21 (8): 42-8. [Gaus O.V., Livzan M.A. Irritable bowel syndrome: what do we know about symptoms today? Consilium Medicum. 2019; 21 (8): 42-8 (in Russian).]</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Ливзан М.А., Гаус О.В., Турчанинов Д.В., Попелло Д.В. Синдром абдоминальнои боли в мо-лодежнои среде: распространенность и факторы риска. Эксперим. и клин. гастроэнтерология. 2019; 170 (10): 12-7.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Sinagra E, Morreale GE, Mohammadian G et al. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immune-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23 (36): 6593-627.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Костенко М.Б., Ливзан М.А. Механизмы развития синдрома раздраженного кишечника. Сиб. журн.гастроэнтерологии и гепатологии. 2000;10: 32.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol 2014; 11: 497-505.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Khan I, Ullah N, Zha L et al. Alteration of the gut microbiota in inflammatory bowel disease (IBD): cause of consequence? IBD treatment targeting the gut microbiome. Pathogens 2019; 8 (3): 126.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Mentella MC, Scaldaferri F, Pizzoferrato M et al. Nutrition, IBD and gut microbiota: a review. Nutrients 2020; 12 (4): 944.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Ливзан М.А., Мозговой С.И., Кононов А.В. Гастрит после эрадикации Helicobacter pylori -простые следы или серьезные последствия? Лечащий врач. 2011; 7: 7.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Tilg G, Schmiderer A, Djanani A. Gut microbiom - immune crosstalk affects progression of cancer. Transl Gastroenterol Hepatol 2018; 3: 34.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Глобальные практические рекомендации Всемирной Гастроэнтерологической Организации. Пробиотики и пребиотики. https://www.worldgastroenterology.org/UserFiles/file/guidelines/pro-biotics-and-prebiotics-russian-2017.pdf</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Harper A, Naghibi M, Garcha D. The role of bacteria, probiotics and diet in irritable bowel syndrome. Foods 2018; 7 (2): 13.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Kankaanpaa P, Sutas Y Salminen S, Isolauri E. Homogenates derived from probiotic bacteria provide down-regulatory signals for peripheral blood mononuclear cells. Food Chemistry 2003; 83 (2): 269-77.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Bodera P, Chcialowski A. Immunomodulatory effect of probiotic bacteria. Recent Pat Inflamm Allergy Drug Discov 2009; 3 (1): 58-64.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Maroof H, Mohammad Hassan Z, Mohabati Mobarez A, Azimi Mohamadabadi M. Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J Clin Immunol 2012; 32: 1353-9.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Ливзан М.А., Костенко М.Б. Место пробиотической терапии в лечении и профилактике ан-тибиотик-ассоциированной диареи. Лечащий врач. 2010; 10: 83.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Ouwehand AC, DongLian C, Weijian X et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study. Vaccine 2014; 2 (4): 458-63.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Goldenberg JZ, Yap C, Lytvyn L et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017; 12: CD006095.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Parker EA, Roy T, D’Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition 2018; 45 (2018): 125-34.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Li B, Liang L, Deng H et al. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Front Pharmacol 2020; 11: 332.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Ахмедов В.А., Орлов И.Н., Гаус О.В. Современные методы реабилитации пациентов с синдромом раздраженного кишечника. Терапия. 2017; 3 (13): 49-55.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Connel M, Shin A, James-Stevenson T et al. Systematic review and meta-analysis: efficacy of patented probiotic, VSL#3, in irritable bowel syndrome. Neurogastroenterol Motil 2018; 30 (12): e13427.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulatio in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol 2018; 18 (1): 71.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Sun J, Wang F, Hu X et al. Clostridium butyricum attenuates chronic unpredictable mild stress-induced depressive-like behavior in mice via the gut-brain axis. J Agric Food Chem 2018; 66 (31): 8415-21.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition 2016; 32 (3): 315-20.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Rao AV, Bested AC, Beaulne TM et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 2009; 1 (1): 6.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry 2017; 16 (1): 14.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Romijn AR, Rucklidge JJ. Systematic review of evidence to support the theory of psychobiotics. Nutr Rev 2015; 73 (10): 675-93.</mixed-citation></ref></ref-list></back></article>
